ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows

New findings from the landmark FLOW trial, unveiled today at the 63rd ERA Congress in Glasgow, confirm that once-weekly semaglutide significantly improves health-related quality of life (HRQoL) for patients battling both type 2 diabetes and chronic kidney disease (CKD). This pivotal data goes beyond previously reported reductions in kidney disease progression, underscoring semaglutide profound impact on patients' daily lives and well-being, not just clinical metrics. This robust HRQoL data solidifies Novo Nordisk market dominance in the burgeoning GLP-1 receptor agonists landscape, particularly as rivals like Eli Lilly's Zepbound/Mounjaro intensify competition. With diabetes and CKD rates soaring globally, the ability to offer a single therapy that enhances both survival and life quality positions semaglutide, marketed as Ozempic and Wegovy, as an even more indispensable tool in a clinician's arsenal, potentially reshaping treatment paradigms for millions of patients facing complex comorbidities. Regulators globally, including the FDA and EMA, are now expected to swiftly review this comprehensive data, paving the way for potential label expansion for semaglutide to explicitly include HRQoL benefits in CKD. This will likely accelerate adoption, further entrenching Novo Nordisk lead and forcing competitors to demonstrate similar holistic patient benefits beyond mere glucose control or weight loss in their own GLP-1 programs, fundamentally raising the bar for future drug development in this therapeutic area.